List view / Grid view
RiboMinus Bacteria 2.0 Transcriptome Isolation Kits perform efficient transcriptome enrichment from total bacterial RNA. Improve your RNA extraction from bacteria today.
This article introduces insights into combatting multidrug resistance via high-throughput laboratory evolution, pointing to the mechanisms of underlying evolved drug resistance.
Learn how Simple Western automated immunoassays screen degraders and IMiD compounds to quantify degradation activity, providing accurate DC50 and Dmax values.
Researchers have shown that CBD can kill Gram-negative bacteria, which could lead to the first new class of antibiotics for resistant bacteria in 60 years.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Scientists have identified a new family of biosynthetic genes in lichens with unknown functions, which could produce new molecules for the pharmaceutical industry.
Researchers at Ingenza and the University of Plymouth are using a machine learning and high‑throughput screening approach to discover novel antimicrobial therapies. In this article, Nikki Withers spoke to one of the researchers, Jack Kay, to hear about the current threat posed by antimicrobial resistance and how he hopes their…
In this journal, find articles discussing antimicrobial resistance, exploring why inhibiting the interaction between SARS-CoV-2 and neuropilin-1 could help combat COVID-19, as well as how CRISPR can be used to enhance productivity in cell line development. Also in this issue, features on engineering new biologic drugs and precision medicine.
An inexpensive molecule showed efficacy against antibiotic-resistant Neisseria gonorrhoeae and Neisseria meningitidis in an animal model.
Altering the mastoparan-L (mast-L) peptide found in Vespula lewisii wasp venom, researchers created several novel antimicrobial molecules.
Exploring how the Ebola virus develops remdesivir resistance has highlighted a mutation that could allow SARS-CoV-2 to do the same.
A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.